Does Prostate Cancer Have Any New Treatment Options?

While treatment for prostate cancer varies, and menprostate gland to freeze and kill cancer cells. A study
have a wide menu of choices, there are a few newwas done involving twenty men who had prostate
treatment options in the works that may soon becancer; all were given focal cryosurgery, and of the
available. A new vaccine, improved cryosurgery, andtwenty, nineteen showed no signs of cancer as much
a new gene-based therapy are currently inas eight years later.
development. The vaccine dubbed Provenge isThe advantage of cryosurgery is that the procedure
currently on the FDA's fast track program,can be successfully performed without resulting in the
cryosurgery has been around for awhile but has seenmajor side effects of traditional prostate removal
some recent advances in technique that make itsurgery, such as impotence and incontinence.
more viable, and the new gene therapy known asAlthough not widely performed, focal cryosurgery is
Ad5-TRAIL involves injecting a virus carrying aa promising new treatment that solves one of the
prostate cancer fighting gene into the prostate glandmajor problems in men facing prostate cancer.
itself. This article will examine the current status andThe third new treatment option is a gene-based
details of these new prostate cancer treatments.therapy called Ad5-TRAIL. The TRAIL gene is able to
Dendreon Corporation's prostate cancer vaccineproduce what's known as apoptosis in cells, which is a
known as Provenge is the most promising new"planned" cell death, as opposed to necrosis, which is
treatment of the three. Intended for cancer that hasdeath due to injury. The TRAIL gene is inserted into
spread outside the prostate gland and is so farthe prostate gland via a virus that has been
without symptoms, the vaccine "teaches" theengineered to not reproduce, and passes the
patient's immune cells to attack the cancer. Havingprogram for apoptosis on to the tumor cells, which
just finished its second Phase 3 trial, the drug hasthen die.
shown a 30% increase in survival rates amongThe advantage to this therapy is that the
advanced prostate cancer patients. Since it fills in aprogrammed cell death only affects cancerous cells
much-needed gap in the prostate cancer treatmentand leaves normal cells alone. The treatment is still in
field, it has been granted "fast track" status with theits infancy and is currently only in Phase I of its clinical
United States' Federal Drug Administration, which willtrial.
hopefully speed along the approval process. WhileThe future looks hopeful for prostate cancer. New
Provenge may be useful for advanced prostatetreatment options are in their infancy, but a few are
cancer, there is a new surgery for cancer patients inon the verge of becoming reality. Provenge is on
whom the disease is confined to the prostate gland.track to FDA approval, and focal cryosurgery is
Also known as the "male lumpectomy," cryosurgeryavailable today. While Ad5-TRAIL gene therapy is
has been around for some decades. However, someyears away from becoming a viable treatment, it
recent advances in it have increased its potentialperhaps looks the most promising as a targeted,
effectiveness. The latest incarnation, focalgene-based therapy that directly attacks only cancer
cryosurgery, uses argon gas injected directly into thecells.